β-Amyloid (18-28) is a peptide fragment of β-Amyloid.
β-Amyloid 18-28 is a synthetic peptide fragment derived from the amyloid precursor protein, encompassing amino acid residues 18 to 28 of the β-amyloid (Aβ) sequence. As a discrete region within the larger Aβ peptide, it is notable for its involvement in protein aggregation phenomena and its relevance to neurodegenerative disease research, particularly studies focused on Alzheimer's disease pathology. The unique sequence and biophysical properties of this peptide make it a valuable tool for dissecting the molecular determinants of amyloid formation, peptide-protein interactions, and structure-function relationships in amyloidogenic pathways.
Aggregation studies: Researchers utilize β-Amyloid 18-28 to investigate the fundamental mechanisms of peptide aggregation and fibrillogenesis. Its defined sequence allows for controlled in vitro experiments assessing the kinetics and thermodynamics of oligomer and fibril formation. By examining how this fragment self-associates or interacts with other amyloidogenic sequences, scientists can delineate the minimal structural motifs required for amyloid assembly, providing insight into the early events of plaque formation and protein misfolding disorders.
Structure-activity relationship analysis: The peptide serves as a model substrate for structure-activity relationship (SAR) studies, enabling detailed exploration of how specific amino acid residues contribute to amyloidogenicity and biological activity. By subjecting β-Amyloid 18-28 to modifications such as point mutations, truncations, or chemical labeling, researchers can systematically probe the effects on secondary structure, aggregation propensity, and interaction with cellular components. These investigations support the rational design of peptides or small molecules aimed at modulating amyloid behavior.
Protein interaction mapping: β-Amyloid 18-28 is frequently employed to examine binding interactions with a variety of molecular partners, including chaperones, antibodies, and cellular receptors. Its defined epitope allows for precise mapping of interaction domains, aiding in the identification of critical contact points involved in recognition and binding. Such studies are instrumental in elucidating the molecular underpinnings of amyloid toxicity, immune recognition, and cellular uptake processes relevant to neurodegeneration research.
Analytical assay development: The peptide fragment is a valuable standard or probe in the development and optimization of analytical assays targeting amyloid species. It can be incorporated into enzyme-linked immunosorbent assays (ELISA), mass spectrometry protocols, or fluorescence-based detection platforms to calibrate sensitivity, validate specificity, or benchmark analytical performance. Its predictable behavior and sequence fidelity make it an ideal reference for quantifying amyloid content or screening for amyloid-modulating agents in biochemical workflows.
Peptide synthesis and methodological validation: β-Amyloid 18-28 is also utilized as a model peptide in the optimization and validation of solid-phase peptide synthesis (SPPS) protocols and purification techniques. Its moderate length and well-characterized sequence facilitate troubleshooting of coupling efficiencies, resin selection, and chromatographic separation methods. By employing this peptide as a test substrate, laboratories can refine synthesis parameters, improve yield, and ensure reproducibility in peptide production pipelines, supporting broader peptide research initiatives.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More